反应详情

In a similar manner to that described in example 196, from ethyl 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxylate (30 mg, 0.084 mmol) described in example 92, triethylamine (0.5 mL, 4.08 mmol), and {2-[4-(methylsulfonyl)phenyl]ethyl}amine (250 mg, 1.25 mmol), was prepared 7-[(4-fluorophenyl)methyl]-4-hydroxy-1-methyl-N-{2-[4-(methylsulfonyl)phenyl]ethyl}-2-oxo-1,2-dihydro-1,5-naphthyridine-3-carboxamide (11 mg, 26% yield) as a white solid after purification by reverse phase HPLC. 1H NMR (CDCl3) δ 10.28 (br s, 1 H), 8.56 (s, 1 H), 7.87 (d, J=8 Hz, 2 H), 7.44 (d, J=8 Hz, 2 H), 7.38 (s, 1 H), 7.16-7.14 (m, 2 H), 7.04-6.99 (m, 2 H), 4.13 (s, 2 H), 3.72 (m, 2 H), 3.56 (s, 3 H), 3.06-3.02 (m, 5 H); HRMS m/z calcd for: C26H25FN3O5S: 510.1493. Found: 510.1498.